GT Biopharma closed at $4.84 on Nov 4, down 8.16%, within 0.0% of its 52-week closing low. Volume of 69.1K shares was 1.16× its 20-day average (close to normal).
Split-adjusted performance: -24.0% over one month, -51.9% over six months, -68.9% over one year.
Short interest was 278.8K shares at the Oct 15 settlement, up 7.5% from the prior report (24.1% of float, 7.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GTBPGT Biopharma | $4.84 | −8.16% | −51.9% | — | — | — | $8.7M | |
| TOVXTheriva Biologics | $0.1900 | +4.40% | −50.3% | — | — | — | $8.7M | Compare |
| LTRNLantern Pharma | $0.5866 | −2.61% | −72.6% | — | — | — | $8.8M | Compare |
| MTVAMetaVia | $1.34 | +6.35% | −4.3% | — | — | — | $8.8M | Compare |
| MBRXMoleculin Biotech | $8.46 | +1.93% | −82.9% | — | — | — | $8.6M | Compare |
| ACTUActuate Therapeutics | $0.3699 | +5.69% | −87.6% | — | — | — | $8.9M | Compare |
| LEXXLexaria Bioscience | $4.07 | +0.99% | −59.8% | −100.0% | — | — | $8.6M | Compare |
| CURXCuranex Pharmaceuticals | $5.80 | −6.30% | −17.7% | — | — | — | $9.1M | Compare |
| CALCCalciMedica | $1.35 | −8.50% | −56.8% | — | — | — | $9.2M | Compare |
No recent articles focused on GT Biopharma. 2 articles mention it in passing.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
